Complain about a product or service

Promising Alzheimer’s Discovery Reported

Protein reverses learning problems in mice

October 8, 2007

• Money Management Problems Could Be Alzheimer's Warning • Mediterranean Diet Linked With Lower Risk Of Alzheimer's Disease • High Cholesterol In Midlife Raises Risk Of Late-Life Dementia • Some Blood Pressure Drugs May Help Protect Against Dementia • Study Suggests Earlier Alzheimer's Treatment • Alzheimer's Cases Rise Among "Oldest Old" • Researchers Find Caffeine Effective Alzheimer’s Treatment • Landmark Alzheimer's Drug Cleared For Clinical Trials • Blood Test May Diagnose Alzheimer's • Diet May Be Factor in Memory Retention • Insulin May Combat Alzheimer's • Moderate Drinking Can Reduce Risks of Alzheimer's • Daily Pill Said To Stop Alzheimer's • Low Levels of 'Good Cholesterol' Linked to Memory Loss, Dementia Risk • Chemical in Celery May Fight Alzheimer's • Dementia Linked To Obesity • Studies Find Link Between Diabetes and Alzheimer's --- • Index to all Alzheimer's stories

In the last two years medical researchers have made a number of strides in understanding, and potentially treating, Alzheimer’s disease, whose victims gradually lose all memory and ultimately die. The latest promising development comes from St. Louis University.

SLU researchers say they have found that a special protein can be injected into the body to reverse learning problems in mice that have an animal version of Alzheimer’s disease.

The protein -- part of the immunoglobulin M (IgM) class -- is an antibody that grabs onto the amyloid beta protein in the brain and prevents it from changing into the toxic substance believed to cause Alzheimer’s disease.

“Our research in an animal model showed that antibodies can be developed rationally for treating Alzheimer’s disease,” said William A. Banks, M.D. professor of geriatrics and pharmacological and physiological science at Saint Louis University.

“It’s a major thing that people have been trying to do – get antibodies into the brain in the right amount to treat illnesses. This antibody does that.”

Banks says the findings are surprising because IgM is five times bigger than the antibody immunoglobulin G (IgG), which has already been studied as a potential therapy for Alzheimer’s disease. Because it is larger, scientists didn’t believe it could cross the blood-brain barrier, a protective membrane that keeps foreign substances out of the brain.

“We collaborated with Michael Steinitz from Hebrew University in Jerusalem, who developed an antibody that is part of the IgM class of antibodies that would stick better to amyloid beta protein,” said Banks, who also is a staff physician at Veterans Affairs Medical Center in St. Louis.

“This compound had better entry to the brain than IgG, even though they are smaller.”

A single intravenous dose of IgM reversed cognitive impairment in aged mice that have a genetic mutation that causes deficits similar to those found in patients with Alzheimer’s disease, Banks said.

The findings were published in the August issue of Experimental Neurology.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.